Uncategorized
OptiKira Awarded Phase II SBIR Grant
CLEVELAND--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/BioMotiv?src=hash" target="_blank"gt;#BioMotivlt;/agt;--OptiKira announced today that it was awarded a Phase II SBIR grant to support continued development of a new treatment for retinitis pigmentosa.